JP2002541120A - 血液細胞の増殖阻害用及び自動免疫疾患の治療用カスパーゼ阻害剤 - Google Patents

血液細胞の増殖阻害用及び自動免疫疾患の治療用カスパーゼ阻害剤

Info

Publication number
JP2002541120A
JP2002541120A JP2000609099A JP2000609099A JP2002541120A JP 2002541120 A JP2002541120 A JP 2002541120A JP 2000609099 A JP2000609099 A JP 2000609099A JP 2000609099 A JP2000609099 A JP 2000609099A JP 2002541120 A JP2002541120 A JP 2002541120A
Authority
JP
Japan
Prior art keywords
caspase
caspase inhibitor
inhibitors
inhibitor according
fmk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000609099A
Other languages
English (en)
Japanese (ja)
Inventor
バッド・ラルフ・シィー
チョップ・ユルグ
孝夫 ▲かた▼岡
Original Assignee
アポテーク・リサーチ・アンド・デベロップメント・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7903644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002541120(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アポテーク・リサーチ・アンド・デベロップメント・リミテッド filed Critical アポテーク・リサーチ・アンド・デベロップメント・リミテッド
Publication of JP2002541120A publication Critical patent/JP2002541120A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000609099A 1999-04-06 2000-04-05 血液細胞の増殖阻害用及び自動免疫疾患の治療用カスパーゼ阻害剤 Withdrawn JP2002541120A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19915465A DE19915465A1 (de) 1999-04-06 1999-04-06 Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
DE19915465.1 1999-04-06
PCT/EP2000/003019 WO2000059536A1 (fr) 1999-04-06 2000-04-05 Inhibiteurs de caspase pour limiter la proliferation de cellules sanguines et pour traiter des maladies autoimmunes

Publications (1)

Publication Number Publication Date
JP2002541120A true JP2002541120A (ja) 2002-12-03

Family

ID=7903644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000609099A Withdrawn JP2002541120A (ja) 1999-04-06 2000-04-05 血液細胞の増殖阻害用及び自動免疫疾患の治療用カスパーゼ阻害剤

Country Status (9)

Country Link
US (2) US20020086832A1 (fr)
EP (1) EP1169056B1 (fr)
JP (1) JP2002541120A (fr)
AT (1) ATE249837T1 (fr)
AU (1) AU4543400A (fr)
CA (1) CA2365825A1 (fr)
DE (2) DE19915465A1 (fr)
ES (1) ES2209871T3 (fr)
WO (1) WO2000059536A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815541B1 (fr) 2000-10-24 2008-02-29 Lipha Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
AU2005215320B2 (en) * 2004-02-24 2008-04-17 Sankyo Company, Limited Amino alcohol compound
WO2009083929A1 (fr) * 2007-12-27 2009-07-09 Theraptosis Inhibiteurs de caspase-1 et utilisations de ceux-ci
WO2009083930A1 (fr) * 2007-12-27 2009-07-09 Theraptosis Inhibiteurs de caspase-8 et utilisations de ceux-ci
WO2014060392A1 (fr) * 2012-10-16 2014-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la caspase 6 pour le traitement de troubles d'activation et/ou de prolifération des lymphocytes t

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578613A (en) * 1897-03-09 Robert fredrick ttmmons
EP0600880B1 (fr) * 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukine 1-beta protease et inhibiteurs d'interleukine 1-beta protease
US5962301A (en) * 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
US5798442A (en) * 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5654146A (en) * 1995-05-31 1997-08-05 Incyte Pharmaceuticals, Inc. Human ice homolog
US6635738B2 (en) * 1996-03-04 2003-10-21 The Trustees Of Columbia University In The City Of New York Compounds which prevent neuronal cell death and uses thereof
EP0842665A3 (fr) * 1996-11-14 2002-12-18 Smithkline Beecham Corporation Protéases d'apoptose de type enzyme de conversion d'interleukine-1-bèta et leurs agonistes
US6623938B2 (en) * 1997-01-21 2003-09-23 Human Genome Sciences, Inc. I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
CN1269722A (zh) * 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
WO1998057664A1 (fr) * 1997-06-19 1998-12-23 The General Hospital Corporation Enzyme de conversion de l'interleukine (ice) et lesions du snc

Also Published As

Publication number Publication date
EP1169056B1 (fr) 2003-09-17
US20040209813A1 (en) 2004-10-21
EP1169056A1 (fr) 2002-01-09
DE50003730D1 (de) 2003-10-23
AU4543400A (en) 2000-10-23
CA2365825A1 (fr) 2000-10-12
WO2000059536A1 (fr) 2000-10-12
DE19915465A1 (de) 2000-10-19
ES2209871T3 (es) 2004-07-01
US20020086832A1 (en) 2002-07-04
ATE249837T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
Fischer et al. Caspase 9–dependent killing of hepatic stellate cells by activated Kupffer cells
EP1560590B1 (fr) Peptides complementaires synthetiques et utilisation ophtalmologique de ceux-ci
TWI510622B (zh) 用於治療及／或預防自體免疫疾病及用於調節性ｔ細胞形成之藥劑
Venge et al. Molecules in focus eosinophil cationic protein (ECP)
Chen et al. Preservation of basal AcSDKP attenuates carbon tetrachloride-induced fibrosis in the rat liver
US8071716B2 (en) Thymus-specific protein
US20080242837A1 (en) Peptide compositions
CN104661672A (zh) 用于预防或治疗败血症的组合物
US20030220260A1 (en) Peptide compositions
KR101184833B1 (ko) Ｈｃｇ 절편들을 포함하는 점막 및 경구 투여용 조성물
WO1993024634A1 (fr) Dipeptidyle peptidase-i, son clonage et agents therapeutiques contenant des inhibiteurs de cette substance
US20040202645A1 (en) Administration of gene-regulatory peptides
JP2002541120A (ja) 血液細胞の増殖阻害用及び自動免疫疾患の治療用カスパーゼ阻害剤
AU2006201501A1 (en) Compositions and methods for caspase-induced apoptosis
JP3030386B2 (ja) 抗ガン剤
Blishchenko et al. Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin β-chain
EP0956864A1 (fr) Inhibiteur de fibrose des tissus
JP3805975B2 (ja) 創傷治癒剤
KR20010043088A (ko) 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 ｃＤＮＡ및 그 용도
ZA200600084B (en) Biologically active peptide comprising Tyrosyl-Seryl-Valine (YSV)
Erdös News about ACE, or, the separate lives of
CA2654956A1 (fr) Peptides a activite anti-proliferative
CN114533874A (zh) Psd-95 gk结构域作为神经保护靶点的用途
US7807626B2 (en) Tumor suppressor protein and nucleotide encoding same
Klostergaard Monocyte/macrophage cytotoxins: candidates as effectors of cell-mediated cytotoxicity and as biological response modifiers

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070605